Trial intelligence / Profile preview

Cangrelor add-on versus standard dual antiplatelet therapy in STEMI after out-of-hospital cardiac arrest during targeted temperature management

2016-003265-26Phase 4Completed

Sponsor
Medical University of Vienna
Start
Nov 2016
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, randomised, open-label trial of cangrelor in myocardial infarction (MI) (2 arms), sponsored by Medical University of Vienna. Started Nov 2016; status: completed.

02

Drugs

cangrelor
03

Conditions

myocardial infarction (MI)

Beyond the preview

Go deeper on 2016-003265-26.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2016-003265-26.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call